Expert opinion on COVID-19 vaccines and cladribine tablets in MS: A plain language summary

Peter Rieckmann; Diego Centonze; Gavin Giovannoni; Le H. Hua; Celia Oreja-Guevara; Daniel Selchen; Per Soelberg Sørensen; Patrick Vermersch; Heinz Wiendl; Hashem Salloukh; Bassem Yamout

doi:10.2217/nmt-2022-0027

Expert opinion on COVID-19 vaccines and cladribine tablets in MS: A plain language summary

Peter Rieckmann
, Diego Centonze
, Gavin Giovannoni
, Le H. Hua
, Celia Oreja-Guevara
, Daniel Selchen
, Per Soelberg Sørensen
, Patrick Vermersch
, Heinz Wiendl
, Hashem Salloukh
, Bassem Yamout^*

^*Corresponding author for this work

Research output: Contribution to journal › Review › peer-review

Abstract

What is this summary about? People with multiple sclerosis (shortened to MS) who are taking cladribine tablets may have concerns about whether they can be vaccinated against COVID-19. This summary details the findings from a previously published article, in which an international committee of 10 MS experts developed recommendations to answer some important questions about COVID-19 vaccines in people with MS (including relapsing-remitting or active secondary progressive disease) taking cladribine tablets. What were the results? The committee identified 13 recommendations, which were all agreed upon by at least three-quarters (75%) of the 38 voting MS experts. Generally, they recommended that people with MS taking cladribine tablets should be vaccinated for COVID-19 as soon as possible, because the vaccine is thought to be both safe and effective, and vaccine responses were not likely to be affected by cladribine tablets. What do the results mean? Overall, people with MS taking cladribine tablets should receive the COVID-19 vaccine to protect themselves, unless advised differently by their healthcare provider. </sec.

Original language	English
Journal	Neurodegenerative Disease Management
Volume	13
Issue number	1
Pages (from-to)	5-13
Number of pages	9
ISSN	1758-2024
DOIs	https://doi.org/10.2217/nmt-2022-0027
Publication status	Published - 2023
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2022 The Authors.

Funding

This study was sponsored by Merck Healthcare KGaA, Darmstadt, Germany (CrossRef Funder ID: 10.13039/100009945). Financial & competing interests disclosure The authors would like to thank everyone who took part in the survey. Plain language summary writing and editing support were provided by R Harris, PhD, and D McWain of Ashfield MedComms (New York, NY, USA), an Inizio company, and was funded by EMD Serono Inc. (Rockland, MA, USA), an affiliate of Merck KGaA (CrossRef Funder ID: 10.13039/100004755). The authors had full control of this summary and provided their final approval of all content. Who sponsored this study?

Keywords

cladribine tablets
clinical research
COVID-19
lay summary
multiple sclerosis
plain language summary
vaccination

Access to Document

10.2217/nmt-2022-0027

Library access?

Check availability at the Royal Danish Library

Cite this

@article{54b44366a7484b4eb5a5396f487274cd,

title = "Expert opinion on COVID-19 vaccines and cladribine tablets in MS: A plain language summary",

abstract = "What is this summary about? People with multiple sclerosis (shortened to MS) who are taking cladribine tablets may have concerns about whether they can be vaccinated against COVID-19. This summary details the findings from a previously published article, in which an international committee of 10 MS experts developed recommendations to answer some important questions about COVID-19 vaccines in people with MS (including relapsing-remitting or active secondary progressive disease) taking cladribine tablets. What were the results? The committee identified 13 recommendations, which were all agreed upon by at least three-quarters (75\%) of the 38 voting MS experts. Generally, they recommended that people with MS taking cladribine tablets should be vaccinated for COVID-19 as soon as possible, because the vaccine is thought to be both safe and effective, and vaccine responses were not likely to be affected by cladribine tablets. What do the results mean? Overall, people with MS taking cladribine tablets should receive the COVID-19 vaccine to protect themselves, unless advised differently by their healthcare provider. ",

keywords = "cladribine tablets, clinical research, COVID-19, lay summary, multiple sclerosis, plain language summary, vaccination",

author = "Peter Rieckmann and Diego Centonze and Gavin Giovannoni and Hua, \{Le H.\} and Celia Oreja-Guevara and Daniel Selchen and S{\o}rensen, \{Per Soelberg\} and Patrick Vermersch and Heinz Wiendl and Hashem Salloukh and Bassem Yamout",

note = "Publisher Copyright: {\textcopyright} 2022 The Authors.",

year = "2023",

doi = "10.2217/nmt-2022-0027",

language = "English",

volume = "13",

pages = "5--13",

journal = "Neurodegenerative Disease Management",

issn = "1758-2024",

publisher = "Future Medicine Ltd.",

number = "1",

}

TY - JOUR

T1 - Expert opinion on COVID-19 vaccines and cladribine tablets in MS

T2 - A plain language summary

AU - Rieckmann, Peter

AU - Centonze, Diego

AU - Giovannoni, Gavin

AU - Hua, Le H.

AU - Oreja-Guevara, Celia

AU - Selchen, Daniel

AU - Sørensen, Per Soelberg

AU - Vermersch, Patrick

AU - Wiendl, Heinz

AU - Salloukh, Hashem

AU - Yamout, Bassem

PY - 2023

Y1 - 2023

N2 - What is this summary about? People with multiple sclerosis (shortened to MS) who are taking cladribine tablets may have concerns about whether they can be vaccinated against COVID-19. This summary details the findings from a previously published article, in which an international committee of 10 MS experts developed recommendations to answer some important questions about COVID-19 vaccines in people with MS (including relapsing-remitting or active secondary progressive disease) taking cladribine tablets. What were the results? The committee identified 13 recommendations, which were all agreed upon by at least three-quarters (75%) of the 38 voting MS experts. Generally, they recommended that people with MS taking cladribine tablets should be vaccinated for COVID-19 as soon as possible, because the vaccine is thought to be both safe and effective, and vaccine responses were not likely to be affected by cladribine tablets. What do the results mean? Overall, people with MS taking cladribine tablets should receive the COVID-19 vaccine to protect themselves, unless advised differently by their healthcare provider.

AB - What is this summary about? People with multiple sclerosis (shortened to MS) who are taking cladribine tablets may have concerns about whether they can be vaccinated against COVID-19. This summary details the findings from a previously published article, in which an international committee of 10 MS experts developed recommendations to answer some important questions about COVID-19 vaccines in people with MS (including relapsing-remitting or active secondary progressive disease) taking cladribine tablets. What were the results? The committee identified 13 recommendations, which were all agreed upon by at least three-quarters (75%) of the 38 voting MS experts. Generally, they recommended that people with MS taking cladribine tablets should be vaccinated for COVID-19 as soon as possible, because the vaccine is thought to be both safe and effective, and vaccine responses were not likely to be affected by cladribine tablets. What do the results mean? Overall, people with MS taking cladribine tablets should receive the COVID-19 vaccine to protect themselves, unless advised differently by their healthcare provider.

KW - cladribine tablets

KW - clinical research

KW - COVID-19

KW - lay summary

KW - multiple sclerosis

KW - plain language summary

KW - vaccination

U2 - 10.2217/nmt-2022-0027

DO - 10.2217/nmt-2022-0027

M3 - Review

C2 - 36278394

AN - SCOPUS:85147935135

SN - 1758-2024

VL - 13

SP - 5

EP - 13

JO - Neurodegenerative Disease Management

JF - Neurodegenerative Disease Management

IS - 1

ER -